Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Teva, Par Win Patent Appeal on Pronova Heart Drug in U.S.

Sept. 12 (Bloomberg) -- Teva Pharmaceuticals USA Inc. and Par Pharmaceutical Cos. won an appeal in their bid to sell a generic version of BASF SE’s heart medicine Lovaza in the U.S.

The U.S. Court of Appeals for the Federal Circuit in a ruling today said it reversed a lower court decision because one patent held by BASF’s Pronova unit had been made publicly accessible and another had expired.

The ruling sent shares of Amarin Corp., the maker of a competing medicine, down as much as 12 percent, the biggest drop since December 2012. Teva’s American depositary receipts, rose 1.1 percent to $38.94 at 12:14 p.m. New York time.

Lovaza is the first and only fish-oil derived prescription drug approved by the U.S. Food and Drug Administration, and Petach Tikva, Israel-based Teva and Par want to market generic versions, the court said in its ruling.

U.S. sales of Lovaza were more than $2.3 billion as of August 2010, the court said.

Pronova was acquired this year by Ludwigshafen, Germany-based BASF, and Par was bought last year by TPG Capital.

To contact the reporter on this story: Todd Shields in Washington at;

To contact the editor responsible for this story: Bernard Kohn at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.